title: Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
abstract: OBJECTIVE
  This report describes a case of kidney failure secondary to orlistat, a lipase inhibitor commonly used in the treatment of obesity.
  
  
  METHODS
  An 80-year-old man with type 2 diabetes who was being treated with orlistat developed rapidly progressive kidney failure. Low-grade albuminuria argued against diabetic nephropathy. Renal biopsy showed tubulointerstitial nephritis associated with numerous calcium oxalate crystals. Enteric hyperoxaluria was attributed to the orlistat treatment. The latter was stopped and the patient received calcium supplements. Six months after orlistat withdrawal, oxaluria was normalized and kidney function stabilized.
  
  
  CONCLUSIONS
  Oxalate nephropathy may result from hyperoxaluria secondary to orlistat treatment. This suggests that kidney function and oxaluria be closely monitored in patients taking orlistat.
authors.affiliation: Division of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
authors.forename: B
authors.initials: B
authors.lastname: Buysschaert
authors.affiliation: Division of Pathology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium; Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Aydin
authors.affiliation: Division of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium; Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Morelle
authors.affiliation: Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium; Division of Endocrinology and Nutrition,Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
authors.forename: M P
authors.initials: MP
authors.lastname: Hermans
authors.affiliation: Division of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium; Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium.
authors.forename: M
authors.initials: M
authors.lastname: Jadoul
authors.affiliation: Division of Nephrology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium; Institute of Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium. Electronic address: nathalie.demoulin@uclouvain.be.
authors.forename: N
authors.initials: N
authors.lastname: Demoulin
mesh_terms: D000369:Aged, 80 and over; D019440:Anti-Obesity Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D006959:Hyperoxaluria; D007674:Kidney Diseases / Q000139:chemically induced*; D007783:Lactones / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D000077403:Orlistat
chemical_list: D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat
keywords: Hyperoxaluria; Orlistat; Oxalate nephropathy